| Drug Name: | Aciclovir (59277-89-3) |
|---|---|
| PubChem ID: | 2022 |
| SMILES: | C1=NC2=C(N1COCCO)NC(=NC2=O)N |
| InchiKey: | MKUXAQIIEYXACX-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 225.208 |
| LogP | : | -1.3318 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 119.05 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Valproic Acid (99-66-1) | Seizures | Antagonistic | not known | Possible interaction between acyclovir and antiepileptic treatment |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Neurologic Symptoms | Myelin basic protein (P02686) | Five patients had an increased myelin basic protein level in cerebrospinal fluid,which may be associated with reversible neurologic symptoms in patients after marrow transplantation. [ ADR Type 1 ] | Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category